Carcinoma, Bronchogenic clinical trials at UC Health
2 research studies open to new patients
open to eligible people ages 1 month and up
This is a Phase 1/2, multi-center, open-label study designed to evaluate the safety and efficacy of LOXO-195 when administered orally to patients age ≥ 1 month and older with NTRK fusion cancers treated with a prior TRK inhibitor.
open to eligible people ages 12 years and up
Phase II, multi-center, open-label study of patients with advanced solid tumors harboring a fusion of NTRK1, NTRK2 or NTRK3.